177 related articles for article (PubMed ID: 23473523)
1. Mechanisms of tumor resistance to small-molecule vascular disrupting agents: treatment and rationale of combination therapy.
Wu XY; Ma W; Gurung K; Guo CH
J Formos Med Assoc; 2013 Mar; 112(3):115-24. PubMed ID: 23473523
[TBL] [Abstract][Full Text] [Related]
2. Vascular disrupting agents: a new class of drug in cancer therapy.
Gaya AM; Rustin GJ
Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):277-90. PubMed ID: 15997924
[TBL] [Abstract][Full Text] [Related]
3. Vascular disrupting agents (VDAs) in anticancer therapy.
Daenen LG; Roodhart JM; Shaked Y; Voest EE
Curr Clin Pharmacol; 2010 Aug; 5(3):178-85. PubMed ID: 20406172
[TBL] [Abstract][Full Text] [Related]
4. Disrupting tumour blood vessels.
Tozer GM; Kanthou C; Baguley BC
Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
[TBL] [Abstract][Full Text] [Related]
5. Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions.
Liang W; Ni Y; Chen F
Oncotarget; 2016 Mar; 7(13):15444-59. PubMed ID: 26812886
[TBL] [Abstract][Full Text] [Related]
6. Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.
Siemann DW; Chaplin DJ; Horsman MR
Cancer Invest; 2017 Sep; 35(8):519-534. PubMed ID: 28872367
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
Close A
Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises.
Van Langendonckt A; Donnez J; Defrère S; Dunselman GA; Groothuis PG
Mol Hum Reprod; 2008 May; 14(5):259-68. PubMed ID: 18430758
[TBL] [Abstract][Full Text] [Related]
9. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.
Chen M; Lei X; Shi C; Huang M; Li X; Wu B; Li Z; Han W; Du B; Hu J; Nie Q; Mai W; Ma N; Xu N; Zhang X; Fan C; Hong A; Xia M; Luo L; Ma A; Li H; Yu Q; Chen H; Zhang D; Ye W
J Clin Invest; 2017 Oct; 127(10):3689-3701. PubMed ID: 28846068
[TBL] [Abstract][Full Text] [Related]
10. Current development status of small-molecule vascular disrupting agents.
Chaplin DJ; Horsman MR; Siemann DW
Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
[TBL] [Abstract][Full Text] [Related]
11. Combination of vascular disrupting agents and ionizing radiation.
Clémenson C; Chargari C; Deutsch E
Crit Rev Oncol Hematol; 2013 May; 86(2):143-60. PubMed ID: 23177097
[TBL] [Abstract][Full Text] [Related]
12. Vascular disrupting agents in cancer therapy.
Smolarczyk R; Czapla J; Jarosz-Biej M; Czerwinski K; Cichoń T
Eur J Pharmacol; 2021 Jan; 891():173692. PubMed ID: 33130277
[TBL] [Abstract][Full Text] [Related]
13. AVE8062: a new combretastatin derivative vascular disrupting agent.
Delmonte A; Sessa C
Expert Opin Investig Drugs; 2009 Oct; 18(10):1541-8. PubMed ID: 19758109
[TBL] [Abstract][Full Text] [Related]
14. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.
Kanthou C; Tozer GM
Int J Exp Pathol; 2009 Jun; 90(3):284-94. PubMed ID: 19563611
[TBL] [Abstract][Full Text] [Related]
15. Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery.
Cooney MM; van Heeckeren W; Bhakta S; Ortiz J; Remick SC
Nat Clin Pract Oncol; 2006 Dec; 3(12):682-92. PubMed ID: 17139319
[TBL] [Abstract][Full Text] [Related]
16. The development and use of vascular targeted therapy in ovarian cancer.
Chase DM; Chaplin DJ; Monk BJ
Gynecol Oncol; 2017 May; 145(2):393-406. PubMed ID: 28238563
[TBL] [Abstract][Full Text] [Related]
17. Vascular targeting therapy: potential benefit depends on tumor and host related effects.
Horsman MR; Bohn AB; Busk M
Exp Oncol; 2010 Sep; 32(3):143-8. PubMed ID: 21403608
[TBL] [Abstract][Full Text] [Related]
18. Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
Cai SX
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):79-101. PubMed ID: 18221055
[TBL] [Abstract][Full Text] [Related]
19. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.
Shaked Y; Ciarrocchi A; Franco M; Lee CR; Man S; Cheung AM; Hicklin DJ; Chaplin D; Foster FS; Benezra R; Kerbel RS
Science; 2006 Sep; 313(5794):1785-7. PubMed ID: 16990548
[TBL] [Abstract][Full Text] [Related]
20. Tumour vascular disrupting agents: combating treatment resistance.
Tozer GM; Kanthou C; Lewis G; Prise VE; Vojnovic B; Hill SA
Br J Radiol; 2008 Oct; 81 Spec No 1():S12-20. PubMed ID: 18819993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]